DRTS

Alpha Tau Medical Ltd · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website alphatau.com
Employees(FY) 94
ISIN nan

Performance

-11.82%

+15.48%

+61.26%

+62.73%

+15.48%

YTD

+7.83%

Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Advanced Technical Analysis

Technical Analysis of DRTS 2025-01-31

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 56 indicating a neutral to slightly bullish outlook, while the Oscillators Score at 40 and the Technical Score at 46 suggest a more cautious stance, leaning towards neutrality. Overall, the combined scores imply a hesitant market sentiment, warranting careful observ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of DRTS

Stock Rank

Recent News & Updates

2025-02-02 19:30
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease(Globenewswire)
2025-01-26 20:00
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day(Globenewswire)
2024-12-17 19:30
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company RandD Update Day(Globenewswire)
2024-12-17 19:30
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day(Yahoo Finance)
2024-12-16 20:00
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor(Globenewswire)
2024-12-10 19:30
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference(Globenewswire)
2024-12-05 19:30
Alpha Tau to Participate in Ladenburg's Oncology Innovators and Investors Symposium(Globenewswire)
2024-12-05 19:30
Alpha Tau to Participate in Ladenburgs Oncology Innovators & Investors Symposium(Yahoo Finance)
2024-11-19 03:00
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-11-12 19:30
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference(Globenewswire)
2024-10-20 20:30
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT for Patients with Recurrent Glioblastoma Multiforme(Globenewswire)
2024-10-10 20:57
Alpha Taus Alpha DaRT Advances Lung Cancer Treatment(Yahoo Finance)
2024-10-09 20:30
Alpha Tau Treats First Patient with Recurrent Lung Cancer(Globenewswire)
2024-09-19 20:30
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT in Immunocompromised Patients with Recurrent cSCC(Globenewswire)
2024-09-16 20:00
Sidoti Events, LLC's Virtual September Small-Cap Conference(Accesswire)
2024-08-21 20:30
Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Con(Globenewswire)
2024-08-14 04:02
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-06-24 20:30
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers(Globenewswire)
2024-05-20 20:45
Alpha Tau to Present at the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-20 09:53
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024(Investorplace)
2024-05-20 04:01
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-05-12 20:30
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer(Globenewswire)
2024-05-05 20:30
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow(Globenewswire)
2024-04-30 20:30
Alpha Tau to Participate in May Investor Conferences(Globenewswire)
2024-03-24 20:50
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit(Globenewswire)
2024-03-07 09:53
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023(Investorplace)
2024-03-07 03:01
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-02-25 19:30
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference(Globenewswire)
2024-01-21 20:40
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?(Zacks)
2023-12-19 20:15
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.